1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 2-2
&NA;,
Preview
|
PDF (825KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
2. |
A stealthy approach to antineoplastic therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 3-4
Sophie Waghorn,
Preview
|
PDF (1626KB)
|
|
摘要:
Liposomal delivery mechanisms are increasingly being seen as a useful vehicle to deliver drugs to the body. A new liposomal formulation has been developed to enable specific targeting of chemotherapy to tumours, delegates were told at the 23rd European Society for Medical Oncology Congress [Athens, Greece; November 1998]. Pegylated-liposomal doxorubicin appears to have superior efficacy over existing therapies in Kaposi's sarcoma, and evidence is starting to show that it is active in other cancers.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
3. |
US guidelines for the use of rotavirus vaccine |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 4-4
&NA;,
Preview
|
PDF (796KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
4. |
Azithromycintreatment of choice for trachoma? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 5-5
&NA;,
Preview
|
PDF (736KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
5. |
‘Great potential’ for self management of anticoagulation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 6-6
&NA;,
Preview
|
PDF (754KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 7-7
&NA;,
Preview
|
PDF (757KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 8-8
&NA;,
Preview
|
PDF (783KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
8. |
Dynorphin A(1-13) may augment opioid analgesia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 9-9
&NA;,
Preview
|
PDF (766KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 10-10
&NA;,
Preview
|
PDF (758KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
10. |
Revealing raloxifene's cardiovascular benefits |
|
Inpharma Weekly,
Volume &NA;,
Issue 1171,
1999,
Page 11-12
Robyn Roper,
Preview
|
PDF (1543KB)
|
|
摘要:
Commencing hormone replacement therapy (HRT) with conjugated estrogens and medroxyprogesterone cannot be recommended for the secondary prevention of coronary heart disease in postmenopausal women, according to the disappointing results from the recent Heart and Estrogen/progestin Replacement Study (HERS).*However, help may be close at hand for postmenopausal women with more promising results being reported from 2 US studies demonstrating cardiovascular protective effects with the selective estrogen receptor modulator, raloxifene. The studies were presented at the 71st Scientific Sessions of the American Heart Association (AHA) [Dallas, US; November 1998].
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|